The company's balance sheet reflects significant volatility, with total assets contracting from $254.2M in 2023Q4 to $175.3M in 2026Q1 alongside a major goodwill impairment.
Prenetics Global Limited (PRE) balance sheet — 7-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Total Current Assets | 147.68M | 83.39M | 86.15M | 93.66M | 241.81M | 106.89M | 43.96M | 15.63M |
| Cash & Short-Term Investments | 109.39M | 61.49M | 62.81M | 72.74M | 184.12M | 45.19M | 14.8M | 11.82M |
| Cash Only | 59.05M | 32.13M | 52.25M | 45.71M | 146.66M | 35.29M | 14.49M | 11.52M |
| Short-Term Investments | 50.34M | 29.36M | 10.56M | 27.03M | 37.46M | 9.91M | 314.71K | 294.06K |
| Accounts Receivable | 5.13M | 2.98M | 5.61M | 5.29M | 42.5M | 47.05M | 23.1M | 2.89M |
| Days Sales Outstanding | 13.94 | 11.78 | 66.81 | 88.87 | 1.18K | 1.37K | 129.34 | 114.34 |
| Inventory | 13.99M | 7.06M | 6.57M | 3.13M | 4.53M | 6.83M | 4.5M | 547.85K |
| Days Inventory Outstanding | 69.48 | 59.07 | 157.45 | 88.39 | 173.36 | 279.13 | 42.27 | 30.68 |
| Other Current Assets | 19.16M | 11.86M | 3.55M | 8.31M | 4.58M | 7.31M | 979.6K | 374.36K |
| Total Non-Current Assets | 5.98M | 120.13M | 127.43M | 160.51M | 70.32M | 41.61M | 34.93M | 14.06M |
| Property, Plant & Equipment | 753K | 1.76M | 7.81M | 5.78M | 13.1M | 13.04M | 4.69M | 2.11M |
| Fixed Asset Turnover | 107.14x | 52.40x | 3.92x | 3.76x | 1.00x | 0.96x | 13.89x | 4.37x |
| Goodwill | 0 | 0 | 37.36M | 29.17M | 33.8M | 3.98M | 3.99M | 3.85M |
| Intangible Assets | 0 | 44.7M | 11.57M | 13.43M | 14.79M | 23.83M | 23.96M | 6.27M |
| Long-Term Investments | 141.34M | 67M | 69.33M | 107.84M | 788.47K | 0 | 0 | 1.66M |
| Other Non-Current Assets | 562K | 6.68M | 1.35M | 4.27M | 7.6M | 693.55K | 2.28M | 161K |
| Total Assets | 153.66M | 203.52M | 213.57M | 254.17M | 312.13M | 148.51M | 78.88M | 29.69M |
| Asset Turnover | 0.78x | 0.45x | 0.14x | 0.09x | 0.04x | 0.08x | 0.83x | 0.31x |
| Asset Growth % | -58.26% | -4.71% | -15.97% | -18.57% | 110.18% | 88.26% | 165.72% | - |
| Total Current Liabilities | 36.56M | 27.67M | 36.55M | 39.48M | 57.2M | 58.74M | 47.07M | 11.9M |
| Accounts Payable | 1.03M | 7.72M | 3.67M | 1.67M | 7.29M | 9.98M | 13.44M | 2.76M |
| Days Payables Outstanding | 28.48 | 64.67 | 87.96 | 47.23 | 278.78 | 407.9 | 126.29 | 154.61 |
| Short-Term Debt | 538K | 1.33M | 0 | 0 | 0 | 1.67M | 15.47M | 0 |
| Deferred Revenue (Current) | 17.38M | 3.09M | 6.49M | 6.11M | 5.67M | 9.59M | 0 | 0 |
| Other Current Liabilities | 30.82M | 15.5M | 15.07M | 15.49M | 17.47M | 22.64M | 10.92M | 7.79M |
| Current Ratio | 4.04x | 3.01x | 2.36x | 2.37x | 4.23x | 1.82x | 0.93x | 1.31x |
| Quick Ratio | 3.66x | 2.76x | 2.18x | 2.29x | 4.15x | 1.70x | 0.84x | 1.27x |
| Cash Conversion Cycle | 54.94 | 6.18 | 136.31 | 130.03 | 1.07K | 1.24K | 45.32 | -9.6 |
| Total Non-Current Liabilities | 24.17M | 1.34M | 5.68M | 4.53M | 11.47M | 490.66M | 804.57K | 930.56K |
| Long-Term Debt | 0 | 437K | 0 | 0 | 0 | 486.4M | 0 | 124.32K |
| Capital Lease Obligations | 1.31M | 437K | 3.01M | 867K | 3.76M | 3.6M | 804.57K | 775.23K |
| Deferred Tax Liabilities | 29K | 8K | 2.17M | 2.62M | 3.19M | 659.5K | 0 | 0 |
| Other Non-Current Liabilities | 24.02M | 460K | 499K | 1.05M | 4.52M | 0 | 0 | 31.01K |
| Total Liabilities | 60.73M | 29.01M | 42.23M | 44.01M | 68.67M | 549.4M | 47.88M | 12.83M |
| Total Debt | 682K | 2.2M | 5.77M | 2.37M | 6.65M | 491.67M | 17.14M | 1.46M |
| Net Debt | -58.37M | -29.93M | -46.48M | -43.34M | -140.01M | 456.38M | 2.65M | -10.07M |
| Debt / Equity | 0.01x | 0.01x | 0.03x | 0.01x | 0.03x | - | 0.55x | 0.09x |
| Debt / EBITDA | -0.01x | - | - | - | - | - | 11.98x | - |
| Net Debt / EBITDA | 1.25x | - | - | - | - | - | 1.86x | - |
| Interest Coverage | -546.51x | -149.26x | -283.25x | -465.40x | -932.14x | -5127.08x | -64.50x | -299.80x |
| Total Equity | 92.92M | 174.51M | 171.35M | 210.16M | 243.46M | -400.89M | 31.01M | 16.85M |
| Equity Growth % | -71.95% | 1.85% | -18.47% | -13.68% | 160.73% | -1392.92% | 83.99% | - |
| Book Value per Share | 5.38 | 12.42 | 13.49 | 18.69 | 48.03 | -108.37 | 4.19 | 2.28 |
| Total Shareholders' Equity | 93.01M | 174.6M | 170.39M | 206.36M | 237.06M | -400.81M | 31.08M | 16.91M |
| Common Stock | 26K | 25K | 19K | 18K | 13.7K | 1.49K | 15.35M | 45.69M |
| Retained Earnings | 0 | 0 | -517.07M | -470.77M | -408.04M | 0 | -43.58M | -41.64M |
| Treasury Stock | 0 | 0 | -639K | -62K | -661.52K | 0 | 0 | 0 |
| Accumulated OCI | 92.99M | 0 | -169.25M | -176.03M | -185.69M | -400.81M | 21.42M | 12.86M |
| Minority Interest | -90K | -93K | 957K | 3.8M | 6.4M | -84.97K | -77.41K | -53.21K |
Quick answers to the most common questions about buying PRE stock.
As of 2025, Prenetics Global Limited (PRE) had total assets of $203.5M including $83.4M in current assets.
Prenetics Global Limited (PRE) carries total debt of $2.2M, offset by $61.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Prenetics Global Limited (PRE) has total shareholders' equity (book value) of $174.6M ($12.42 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Prenetics Global Limited (PRE) reported a current ratio of 3.01x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Rapid cash reserve depletion
Asset Base Contraction Amidst Volatility
According to recent financial filings, Prenetics' total assets declined from $254.2M in 2023Q4 to $175.3M by 2026Q1, reflecting a significant reduction in the company's balance sheet scale as it pivots away from pandemic-era operations toward a more specialized, albeit smaller, clinical diagnostic footprint.
The consistent downward trend in total assets suggests that the company is shedding non-core assets or experiencing a natural decay in pandemic-related infrastructure. Investors should monitor whether this contraction represents a strategic streamlining or a loss of competitive scale in the highly fragmented Asian diagnostic market.
Liquidity Buffer Under Increasing Pressure
As reported in quarterly statements, Prenetics' cash position fluctuated significantly, dropping to $32.1M in 2025Q4 before recovering to $56.0M in 2026Q1, yet this volatility highlights a precarious reliance on external financing to maintain operations while the company continues to burn through its available capital reserves.
While the current ratio of 5.15 in 2026Q1 appears robust on the surface, it is heavily influenced by the timing of cash inflows and does not account for the underlying structural cash burn. The lack of consistent liquidity growth suggests that the company remains vulnerable to sudden shocks in its operating environment.
Asset Composition Reflects Strategic Pivot
Based on the provided balance sheet data, goodwill has experienced significant volatility, peaking at $44.7M in 2025Q4 before dropping to $40.0K in 2026Q1, which suggests a major impairment or restructuring event that warrants further investigation into the quality of the company's historical acquisitions.
The rapid fluctuation in intangible assets indicates that the company's valuation of its acquired businesses is highly sensitive to changing market conditions. This volatility may imply that the firm's long-term strategic investments are not yet yielding the stable, tangible returns necessary to anchor the balance sheet.
Hidden Risks in Equity Structure
As indicated by the financial statements, the company reported zero retained earnings for most of the observed periods, masking the cumulative impact of historical losses that were previously highlighted by a $517.1M deficit in 2024Q4, which suggests a potential accounting reset or reorganization of the equity base.
The absence of retained earnings in recent quarters may obscure the true extent of the company's historical value destruction. Investors should be wary of whether this presentation effectively hides the ongoing impact of persistent operating losses on the company's long-term equity value.